The Clinical Efficacy of Multidose Oritavancin: A Systematic Review

• Egile Nagusiak: Giammarco Baiardi (Egilea), Michela Cameran Caviglia (Egilea), Fabio Piras (Egilea), Fabio Sacco (Egilea), Roberta Prinapori (Egilea), Maria Luisa Cristina (Egilea), Francesca Mattioli (Egilea), Marina Sartini (Egilea), Emanuele Pontali (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2023-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive organisms in adults. The pharmacokinetic/pharmacodynamic (PK/PD) linear kinetic profi...